查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1957799

2026年全球小干擾核糖核酸（RNA）市場報告

Small Interfering Ribonucleic Acid (RNA) Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，小干擾核糖核酸（RNA）市場發展迅速。預計該市場將從2025年的188.6億美元成長到2026年的226.9億美元，年複合成長率（CAGR）達20.3%。過去幾年的成長主要歸功於分子生物學研究的進步、遺傳性和慢性疾病的增加、基於RNA的療法早期取得的成功、基因組學領域研究經費的增加以及RNA干擾機制的建立。

預計未來幾年，小干擾核糖核酸（siRNA）市場將快速成長，到2030年將達到470.7億美元，複合年成長率（CAGR）為20.0%。預測期內的成長要素包括RNA療法監管核准的增加、個人化醫療需求的成長、奈米顆粒遞送技術的創新、製藥公司投資的增加以及siRNA在感染疾病和罕見疾病領域應用的拓展。主要趨勢預計包括RNA干擾療法的臨床應用增加、對標靶基因靜默技術的日益關注、先進siRNA遞送平台的擴展、對精準治療研發投資的增加以及對可擴展RNA生產的更加重視。

未來幾年，對個人化醫療日益成長的需求預計將推動小干擾RNA（siRNA）市場的成長。個人化醫療是一種根據患者的遺傳、環境和生活方式因素量身定做治療方法的醫療策略，旨在改善治療效果和患者護理。基因組學的進步使得精準識別基因變異並開發針對每位患者的個人化治療方法成為可能，推動了對個人化醫療的需求成長。小干擾RNA（siRNA）透過達到精準的基因靜默來支持個人化醫療，並能有效治療特定的遺傳性疾病。透過選擇性抑制致病mRNA，siRNA可以最大限度地減少脫靶效應，提高治療效果和患者預後。例如，據總部位於美國的非營利組織個人化醫療聯盟（PMC）稱，截至2024年2月，美國食品藥物管理局（FDA）在2023年核准了26種新的個人化藥物，高於2022年的12種。因此，對個人化醫療日益成長的需求正在推動小干擾核糖核酸（siRNA）市場的擴張。

在siRNA（小干擾核糖核酸）療法市場中主要企業正致力於獲得監管部門的核准，以開發治療罕見遺傳疾病的創新作用機制，旨在為患者提供持續療效並最大限度地減少給藥頻率。監管部門的核准是指相關機構的正式授權，允許安全地對藥物或治療方法進行測試、上市和給藥。例如，2025年3月，總部位於美國的生物製藥公司Alnilam Pharmaceuticals獲得了美國食品藥物管理局（FDA）對其產品Qfitlia（fitsiran）的核准。這是首個用於治療方法，不論患者是否有抑制因子。該療法旨在透過降低抗凝血酶水平來促進凝血酶的生成，從而支持凝血功能並減少出血事件。 Qfitlia採用皮下注射，每兩個月給藥一次，為血友病治療提供了新的非因子療法選擇。

目錄

第1章：執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球小型相干核糖核酸（RNA）市場：吸引力分數與分析
  • 成長潛力分析、競爭評估、策略適宜性評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 清單：主要原料、資源和供應商
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章：全球市場趨勢與策略

  • 關鍵科技與未來趨勢
    • 生物技術、基因組學和精準醫療
    • 人工智慧（AI）和自主人工智慧
    • 工業4.0和智慧製造
    • 數位化、雲端運算、巨量資料、網路安全
    • 永續性、氣候技術、循環經濟
  • 主要趨勢
    • RNA干擾療法的臨床應用拓展
    • 人們越來越關注標靶基因靜默技術
    • 擴展先進的siRNA遞送平台
    • 增加對精準藥物研發的投資
    • 加強對可擴展RNA生產的關注。

第5章 終端用戶產業市場分析

  • 醫院
  • 研究機構
  • 製藥公司
  • 生技公司
  • 學術機構

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及 COVID-19 疫情對市場的影響。

第7章：全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球小型相干核糖核酸（RNA）市場：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 全球小型相干核糖核酸（RNA）市場規模、比較及成長率分析
  • 全球小型相干核糖核酸（RNA）市場表現：規模與成長，2020-2025年
  • 全球小型相干核糖核酸 (RNA) 市場預測：規模和成長，2025-2030 年，2035 年預測

第8章：全球市場總規模（TAM）

第9章 市場細分

  • 按類型
  • 脂質體全身療法、以奈米顆粒為基礎的全身療法
  • 指示
  • 循環系統疾病、呼吸系統疾病、腫瘤、神經退化性疾病、感染疾病
  • 最終用戶
  • 醫院、研究機構、製藥和生物技術公司、學術機構
  • 按類型細分：脂質體全身療法
  • 陽離子脂質體遞送、中性脂質體遞送、聚乙二醇化脂質體遞送、標靶化脂質體遞送
  • 按類型細分：基於奈米顆粒的全身療法
  • 脂質奈米顆粒遞送、聚合物奈米顆粒遞送、金奈米顆粒遞送、二氧化矽奈米顆粒遞送

第10章 區域與國別分析

  • 全球小型相干核糖核酸 (RNA) 市場：按地區分類，歷史資料及預測，2020-2025 年、2025-2030 年預測、2035 年預測
  • 全球小型相干核糖核酸 (RNA) 市場：依國家分類，歷史資料及預測，2020-2025 年、2025-2030 年預測、2035 年預測

第11章 亞太市場

第12章：中國市場

第13章：印度市場

第14章：日本市場

第15章：澳洲市場

第16章：印尼市場

第17章：韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章 西歐市場

第21章英國市場

第22章：德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章：東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章：南美市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 小干擾核糖核酸（RNA）市場：競爭格局與市場佔有率，2024年
  • 小干擾核糖核酸（RNA）市場：公司估值矩陣
  • 小干擾核糖核酸（RNA）市場：公司概況
    • Novartis AG
    • Thermo Fisher Scientific Inc.
    • GlaxoSmithKline plc
    • Sanofi SA
    • Sarepta Therapeutics Inc.

第37章 其他大型企業和創新企業

  • Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.

第38章：全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 2030年小型相干核糖核酸（RNA）市場：提供新機會的國家
  • 2030年小型相干核糖核酸（RNA）市場：提供新機會的細分市場
  • 2030年小型相干核糖核酸（RNA）市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第41章附錄

簡介目錄
Product Code: PH5MSIRA02_G26Q1

Small interfering ribonucleic acid (RNA) is a short, double-stranded RNA molecule that is crucial for gene silencing through a mechanism known as RNA interference (RNAi). It attaches to complementary messenger RNA (mRNA) sequences, resulting in their degradation and blocking protein production. The main function of siRNA is to control or reduce the expression of specific genes and is often utilized in research and therapeutic settings to target genes that cause diseases.

The main types of small interfering ribonucleic acid (RNA) include liposome-based systemic therapy and nanoparticle-based systemic therapy. Liposome-based systemic therapy is a drug delivery method that utilizes liposomes to carry therapeutic agents throughout the body via the bloodstream. These therapies are applied for various conditions, including cardiovascular diseases, respiratory diseases, oncology, neurodegenerative diseases, and infectious diseases, and serve end users such as hospitals, research institutions, pharmaceutical and biotechnology companies, and academic institutions.

Tariffs are impacting the small interfering ribonucleic acid market by increasing costs of imported nucleotides, lipid nanoparticles, specialized reagents, laboratory instruments, and advanced manufacturing equipment required for siRNA synthesis and delivery. Research institutions and pharmaceutical companies in North America and Europe are most affected due to dependence on imported high-purity raw materials, while Asia-Pacific faces cost pressures on export-oriented production. These tariffs are raising development and production costs and extending clinical timelines. However, they are also encouraging local sourcing of reagents, domestic manufacturing of RNA components, and regional expansion of biopharmaceutical production capabilities.

The small interfering ribonucleic acid (rna) market research report is one of a series of new reports from The Business Research Company that provides small interfering ribonucleic acid (rna) market statistics, including small interfering ribonucleic acid (rna) industry global market size, regional shares, competitors with a small interfering ribonucleic acid (rna) market share, detailed small interfering ribonucleic acid (rna) market segments, market trends and opportunities, and any further data you may need to thrive in the small interfering ribonucleic acid (rna) industry. This small interfering ribonucleic acid (rna) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small interfering ribonucleic acid (rna) market size has grown exponentially in recent years. It will grow from $18.86 billion in 2025 to $22.69 billion in 2026 at a compound annual growth rate (CAGR) of 20.3%. The growth in the historic period can be attributed to advancements in molecular biology research, rising prevalence of genetic and chronic diseases, early success of rna-based therapeutics, increased research funding in genomics, establishment of rna interference mechanisms.

The small interfering ribonucleic acid (rna) market size is expected to see exponential growth in the next few years. It will grow to $47.07 billion in 2030 at a compound annual growth rate (CAGR) of 20.0%. The growth in the forecast period can be attributed to increasing regulatory approvals for rna therapies, growing demand for personalized medicine, expansion of nanoparticle delivery innovations, rising investments by pharmaceutical companies, broader application of sirna in infectious and rare diseases. Major trends in the forecast period include increasing clinical adoption of rna interference therapies, growing focus on targeted gene silencing approaches, expansion of advanced sirna delivery platforms, rising investment in precision therapeutics development, enhanced emphasis on scalable rna manufacturing.

The increasing demand for personalized medicine is anticipated to drive the growth of the small interfering ribonucleic acid (RNA) market in the coming years. Personalized medicine is a medical strategy that customizes treatments for individual patients based on their genetic, environmental, and lifestyle factors to enhance outcomes and improve care. The demand for personalized medicine is rising due to advances in genomic technologies, which allow for the accurate identification of genetic variations and the development of tailored treatments for patients. Small interfering ribonucleic acid (siRNA) supports personalized medicine by enabling precise gene silencing, making it effective for treating specific genetic disorders and diseases. It minimizes off-target effects by selectively inhibiting disease-causing mRNA, thereby improving therapeutic efficacy and patient outcomes. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 approvals in 2022. Consequently, the growing demand for personalized medicine is fueling the expansion of the small interfering ribonucleic acid (RNA) market.

Major companies operating in the small interfering ribonucleic acid (siRNA) therapeutics market are concentrating on obtaining regulatory approvals for innovative mechanisms to treat rare genetic disorders, aiming to provide long-lasting effects and minimize dosing frequency for patients. Regulatory approvals are official authorizations from authorities permitting a drug or therapy to be safely tested, marketed, or administered to patients. For example, in March 2025, Alnylam Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Qfitlia (fitusiran), the first small interfering ribonucleic acid (siRNA)-based therapy for adults and adolescents aged 12 years and older with hemophilia A or B, with or without inhibitors. The therapy is designed to reduce antithrombin levels, thereby increasing thrombin generation to support clot formation and decrease bleeding episodes. Qfitlia provides a subcutaneous, once-every-two-month dosing schedule, offering a novel, non-factor therapeutic option for hemophilia management.

In May 2025, AbbVie Inc., a US-based biopharmaceutical company, formed a partnership with ADARx Pharmaceuticals Inc. Through this collaboration, AbbVie Inc. aims to combine ADARx Pharmaceuticals Inc.'s proprietary RNA technology with its scientific expertise to develop next-generation small interfering RNA (siRNA) therapies, advancing progress in neuroscience, immunology, and oncology. ADARx Pharmaceuticals Inc. is a biotechnology company focused on developing small interfering ribonucleic acid (siRNA)-based therapies that target specific mRNA to treat diseases.

Major companies operating in the small interfering ribonucleic acid (rna) market are Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Sanofi S.A., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.

North America was the largest region in the small interfering ribonucleic acid (RNA) market in 2025. The regions covered in the small interfering ribonucleic acid (rna) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the small interfering ribonucleic acid (rna) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small interfering ribonucleic acid (RNA) market consists of revenues earned by entities by providing services such as gene silencing assays, delivery system development, molecular diagnostics, preclinical testing, and laboratory research support. The market value includes the value of related goods sold by the service provider or included within the service offering. The small interfering ribonucleic acid (RNA) market also includes sales of synthesis kits, lipid nanoparticles, delivery vectors, RNAi assay kits, transfection reagents, and RNA extraction kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Small Interfering Ribonucleic Acid (RNA) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses small interfering ribonucleic acid (rna) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for small interfering ribonucleic acid (rna) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The small interfering ribonucleic acid (rna) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Liposome Systemic Therapy; Nanoparticle-Based Systemic Therapy
  • 2) By Indication: Cardiovascular Diseases; Respiratory Diseases; Oncology; Neurodegenerative Diseases; Infectious Diseases
  • 3) By End-User: Hospital; Research Institutions; Pharmaceutical And Biotechnology Companies; Academic Institutions
  • Subsegments:
  • 1) By Liposome Systemic Therapy: Cationic Liposome Delivery; Neutral Liposome Delivery; Pegylated Liposome Delivery; Targeted Liposome Delivery
  • 2) By Nanoparticle-Based Systemic Therapy: Lipid Nanoparticle Delivery; Polymer Nanoparticle Delivery; Gold Nanoparticle Delivery; Silica Nanoparticle Delivery
  • Companies Mentioned: Novartis AG; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc; Sanofi S.A.; Sarepta Therapeutics Inc.; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Wave Life Sciences Ltd.; Silence Therapeutics plc; Arrowhead Pharmaceuticals Inc.; Quark Pharmaceuticals Inc.; Arbutus Biopharma Corporation; Evox Therapeutics Ltd.; Phio Pharmaceuticals Inc.; Genecon Biotechnologies Co. Ltd.; Olix Pharmaceuticals Inc.; Benitec Biopharma Ltd.; Bio-Path Holdings Inc.; Calando Pharmaceuticals Inc.; Sirnaomics Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Small Interfering Ribonucleic Acid (RNA) Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Small Interfering Ribonucleic Acid (RNA) Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Small Interfering Ribonucleic Acid (RNA) Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Small Interfering Ribonucleic Acid (RNA) Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Increasing Clinical Adoption Of RNA Interference Therapies
    • 4.2.2 Growing Focus On Targeted Gene Silencing Approaches
    • 4.2.3 Expansion Of Advanced siRNA Delivery Platforms
    • 4.2.4 Rising Investment In Precision Therapeutics Development
    • 4.2.5 Enhanced Emphasis On Scalable RNA Manufacturing

5. Small Interfering Ribonucleic Acid (RNA) Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Research Institutions
  • 5.3 Pharmaceutical Companies
  • 5.4 Biotechnology Companies
  • 5.5 Academic Institutions

6. Small Interfering Ribonucleic Acid (RNA) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Small Interfering Ribonucleic Acid (RNA) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Small Interfering Ribonucleic Acid (RNA) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Small Interfering Ribonucleic Acid (RNA) Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Small Interfering Ribonucleic Acid (RNA) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Small Interfering Ribonucleic Acid (RNA) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Small Interfering Ribonucleic Acid (RNA) Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Small Interfering Ribonucleic Acid (RNA) Market Segmentation

  • 9.1. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Liposome Systemic Therapy, Nanoparticle-Based Systemic Therapy
  • 9.2. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases
  • 9.3. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospital, Research Institutions, Pharmaceutical And Biotechnology Companies, Academic Institutions
  • 9.4. Global Small Interfering Ribonucleic Acid (RNA) Market, Sub-Segmentation Of Liposome Systemic Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cationic Liposome Delivery, Neutral Liposome Delivery, Pegylated Liposome Delivery, Targeted Liposome Delivery
  • 9.5. Global Small Interfering Ribonucleic Acid (RNA) Market, Sub-Segmentation Of Nanoparticle-Based Systemic Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Lipid Nanoparticle Delivery, Polymer Nanoparticle Delivery, Gold Nanoparticle Delivery, Silica Nanoparticle Delivery

10. Small Interfering Ribonucleic Acid (RNA) Market Regional And Country Analysis

  • 10.1. Global Small Interfering Ribonucleic Acid (RNA) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Small Interfering Ribonucleic Acid (RNA) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market

  • 11.1. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Small Interfering Ribonucleic Acid (RNA) Market

  • 12.1. China Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Small Interfering Ribonucleic Acid (RNA) Market

  • 13.1. India Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Small Interfering Ribonucleic Acid (RNA) Market

  • 14.1. Japan Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Small Interfering Ribonucleic Acid (RNA) Market

  • 15.1. Australia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Small Interfering Ribonucleic Acid (RNA) Market

  • 16.1. Indonesia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Small Interfering Ribonucleic Acid (RNA) Market

  • 17.1. South Korea Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Small Interfering Ribonucleic Acid (RNA) Market

  • 18.1. Taiwan Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Small Interfering Ribonucleic Acid (RNA) Market

  • 19.1. South East Asia Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Small Interfering Ribonucleic Acid (RNA) Market

  • 20.1. Western Europe Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Small Interfering Ribonucleic Acid (RNA) Market

  • 21.1. UK Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Small Interfering Ribonucleic Acid (RNA) Market

  • 22.1. Germany Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Small Interfering Ribonucleic Acid (RNA) Market

  • 23.1. France Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Small Interfering Ribonucleic Acid (RNA) Market

  • 24.1. Italy Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Small Interfering Ribonucleic Acid (RNA) Market

  • 25.1. Spain Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market

  • 26.1. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Small Interfering Ribonucleic Acid (RNA) Market

  • 27.1. Russia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Small Interfering Ribonucleic Acid (RNA) Market

  • 28.1. North America Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Small Interfering Ribonucleic Acid (RNA) Market

  • 29.1. USA Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Small Interfering Ribonucleic Acid (RNA) Market

  • 30.1. Canada Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Small Interfering Ribonucleic Acid (RNA) Market

  • 31.1. South America Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Small Interfering Ribonucleic Acid (RNA) Market

  • 32.1. Brazil Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Small Interfering Ribonucleic Acid (RNA) Market

  • 33.1. Middle East Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Small Interfering Ribonucleic Acid (RNA) Market

  • 34.1. Africa Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Small Interfering Ribonucleic Acid (RNA) Market Regulatory and Investment Landscape

36. Small Interfering Ribonucleic Acid (RNA) Market Competitive Landscape And Company Profiles

  • 36.1. Small Interfering Ribonucleic Acid (RNA) Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Small Interfering Ribonucleic Acid (RNA) Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Small Interfering Ribonucleic Acid (RNA) Market Company Profiles
    • 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Small Interfering Ribonucleic Acid (RNA) Market Other Major And Innovative Companies

  • Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.

38. Global Small Interfering Ribonucleic Acid (RNA) Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Small Interfering Ribonucleic Acid (RNA) Market

40. Small Interfering Ribonucleic Acid (RNA) Market High Potential Countries, Segments and Strategies

  • 40.1 Small Interfering Ribonucleic Acid (RNA) Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Small Interfering Ribonucleic Acid (RNA) Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Small Interfering Ribonucleic Acid (RNA) Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer